Search

Your search keyword '"Pomponio G"' showing total 144 results
Start Over Author "Pomponio G"
144 results on '"Pomponio G"'

5. Increased prevalence of small airways dysfunction in patients with systemic sclerosis as determined by impulse oscillometry

Author

Bonifazi, M, Sverzellati, N, Negri, E, Pomponio, G, Seletti, V, Bonini, M, Fraticelli, P, Paolini, L, Mattioli, M, Franchi, M, Tramacere, I, Poletti, V, La Vecchia, C, Gasparini, S, Gabrielli, A, Bonifazi, Martina, Sverzellati, Nicola, Negri, Eva, Pomponio, Giovanni, Seletti, Valeria, Bonini, Matteo, Fraticelli, Paolo, Paolini, Luca, Mattioli, Massimo, Franchi, Matteo, Tramacere, Irene, Poletti, Venerino, La Vecchia, Carlo, Gasparini, Stefano, Gabrielli, Armando, Bonifazi, M, Sverzellati, N, Negri, E, Pomponio, G, Seletti, V, Bonini, M, Fraticelli, P, Paolini, L, Mattioli, M, Franchi, M, Tramacere, I, Poletti, V, La Vecchia, C, Gasparini, S, Gabrielli, A, Bonifazi, Martina, Sverzellati, Nicola, Negri, Eva, Pomponio, Giovanni, Seletti, Valeria, Bonini, Matteo, Fraticelli, Paolo, Paolini, Luca, Mattioli, Massimo, Franchi, Matteo, Tramacere, Irene, Poletti, Venerino, La Vecchia, Carlo, Gasparini, Stefano, and Gabrielli, Armando

Abstract

Objectives: The prevalence and clinical implications of small airways involvement in SSc are still to be fully elucidated. The goal of the present work is to assess the prevalence of small airways dysfunction by impulse oscillometry and to determine whether it correlates with selected disease-related features and respiratory-related quality of life. Methods: Ninety-four SSc patients and 93 healthy controls were studied by impulse oscillometry measurements. Small airways dysfunction was defined as the difference between resistance at low frequency, i.e. 5 Hz, and resistance at high frequency, i.e. 20 Hz, termed 'R5-R20', ≥0.07 kPa/l/s. The St George's Respiratory Questionnaire was used to measure health impairment in SSc patients. Radiological features of small airways disease and parenchymal abnormalities on high resolution CT chest scans were jointly assessed by two thoracic radiologists. Results: Small airways dysfunction was present in 21.5% of the SSc patient cohort, with a prevalence almost 5-fold higher compared with controls, and it was significantly associated with worse respiratory-related quality of life. Radiological features consistent with small airways abnormalities were detected in 25% of SSc patients, mostly in the absence of interstitial lung changes. Combining functional and radiological evaluations, one-third of the SSc cohort showed at least one feature of small airways involvement, which was associated with the lcSSc phenotype and with longer disease duration. Conclusion: The current study strengthens the hypothesis that small airway dysfunction might be a feature of SSc-related lung involvement, providing the first data on its significant impact on respiratory-related quality of life. A full assessment of lung function in SSc patients should include impulse oscillometry as a complementary technique, due to potential clinical and therapeutic implications.

Published
2020

6. Increased prevalence of small airways dysfunction in patients with systemic sclerosis as determined by impulse oscillometry

Author

Bonifazi, M., Sverzellati, N., Negri, E., Pomponio, G., Seletti, V., Bonini, M., Fraticelli, P., Paolini, L., Mattioli, M., Franchi, M., Tramacere, I., Poletti, V., La Vecchia, C., Gasparini, S., Gabrielli, A., Bonini M. (ORCID:0000-0002-3042-0765), Franchi M., Bonifazi, M., Sverzellati, N., Negri, E., Pomponio, G., Seletti, V., Bonini, M., Fraticelli, P., Paolini, L., Mattioli, M., Franchi, M., Tramacere, I., Poletti, V., La Vecchia, C., Gasparini, S., Gabrielli, A., Bonini M. (ORCID:0000-0002-3042-0765), and Franchi M.

Abstract

Objectives: The prevalence and clinical implications of small airways involvement in SSc are still to be fully elucidated. The goal of the present work is to assess the prevalence of small airways dysfunction by impulse oscillometry and to determine whether it correlates with selected disease-related features and respiratory-related quality of life. Methods: Ninety-four SSc patients and 93 healthy controls were studied by impulse oscillometry measurements. Small airways dysfunction was defined as the difference between resistance at low frequency, i.e. 5 Hz, and resistance at high frequency, i.e. 20 Hz, termed 'R5-R20', ≥0.07 kPa/l/s. The St George's Respiratory Questionnaire was used to measure health impairment in SSc patients. Radiological features of small airways disease and parenchymal abnormalities on high resolution CT chest scans were jointly assessed by two thoracic radiologists. Results: Small airways dysfunction was present in 21.5% of the SSc patient cohort, with a prevalence almost 5-fold higher compared with controls, and it was significantly associated with worse respiratory-related quality of life. Radiological features consistent with small airways abnormalities were detected in 25% of SSc patients, mostly in the absence of interstitial lung changes. Combining functional and radiological evaluations, one-third of the SSc cohort showed at least one feature of small airways involvement, which was associated with the lcSSc phenotype and with longer disease duration. Conclusion: The current study strengthens the hypothesis that small airway dysfunction might be a feature of SSc-related lung involvement, providing the first data on its significant impact on respiratory-related quality of life. A full assessment of lung function in SSc patients should include impulse oscillometry as a complementary technique, due to potential clinical and therapeutic implications.

Published
2020

7. Tocilizumab in COVID‐19 interstitial pneumonia

Author

Pomponio, G., primary, Ferrarini, A., additional, Bonifazi, M., additional, Moretti, M., additional, Salvi, A., additional, Giacometti, A., additional, Tavio, M., additional, Titolo, G., additional, Morbidoni, L., additional, Frausini, G., additional, Onesta, M., additional, Amico, D., additional, Rocchi, M. L. B., additional, Menzo, S., additional, Zuccatosta, L., additional, Mei, F., additional, Menditto, V., additional, Svegliati, S., additional, Donati, A., additional, D'Errico, M. M., additional, Pavani, M., additional, and Gabrielli, A., additional

Published
2021
Full Text
View/download PDF

15. S.13.1 Safety and efficacy of rituximab in SSc: an analysis from the European Scleroderma Trial and Research Group

Author

Jordan, S., Distler, J., Maurer, B., Allanore, Y., Van Laar, J., Distler, O., Fraticelli, P., Pomponio, G., Gabrielli, B., Riboldi, P., Ferraccioli, G., Valentini, G., Bombardieri, S., Malorni, W., Gerli, R., Lunardi, C., Faggioli, P., Corvetta, A., Gabrielli, A., Ghassemi, P., Baron, M., Blati, M., Kapoor, M., Della Rossa, A., Casigliani, S., Doveri, M., D'Ascanio, A., Tavoni, A., and Bazzichi, L.

Abstract

Objectives. Objective of this multicentre, observational study was to assess effects and safety of rituximab (RTX) using the European Scleroderma Trial and Research Group (EUSTAR) cohort. Methods. EUSTAR centres were asked to provide specific data about SSc patients treated with RTX. Primary endpoints were predefined for different disease manifestations and compared between baseline and follow-up. Normally distributed data, analysed by paired t-test, are shown as mean (s.d.), and non-parametric data, analysed by Wilcoxon matched paired signed-rank test, are shown as median and interquartile range. Results. Data on 72 SSc patients treated with RTX were captured from 27 EUSTAR centres (51 females/21 males, 52 diffuse/19 limited, age 51 (44-60) years, disease duration 6 (3-10) years, 47 anti-Scl-70 positive). The most frequent RTX application scheme was 1000 mg × 2 within 2 weeks (57/72 patients). Co-treatment with other immunosuppressive drugs was reported in 28 patients. The modified Rodnan skin score (mRSS) significantly decreased vs baseline at 7 (5-9) months follow-up (n = 47, 18.2 + 10.9 vs 14.5 + 9.9, P = 0.0002). This was true for both patients with later disease stages and also for patients with earlier, extended skin fibrosis (dSSc with mRSS >16 at baseline, n = 26; 26.5 + 6.8 vs 20.4 + 8.9, P < 0.0001, reduction by 29.9%). S-HAQ was unchanged, but the European SSc activity score improved after rituximab treatment [n = 10; 3.7 (2.6-6.4) vs 1.7 (0.9-2.5), P = 0.01]. RTX had no effects on lung fibrosis (FVC, DLCO, TLC, HRCT score) in n = 11 patients with evidence for SSc-ILD. In SSc-polyarthritis patients, the DAS-28 declined at 6 months follow-up without reaching statistical significance [n = 8; 4.8 (2.5-7.5) vs 3.7 (2.6-6.6); p = 0.3]. Of 8, 5patients were RF and/or anti-CCP antibody positive. Similar results were obtained for secondary outcome measures (tender and swollen joint count, VAS, CRP, ESR). Additional positive effects of RTX were seen on SSc-related myopathy (CK levels, 273 + 177 vs 184 + 139; n = 12, P = 0.03) and on digital ulcers [total number per patient 1 (1-3) vs 0 (0-1); n = 23; P = 0.0086]. During RTX treatment 14 patients had infections, 3 serum sickness, 2 allergic reactions and 1 lung fibrosis aggravation, 29 fatigue and 9 nausea. Four patients died, one possibly related to RTX treatment (pneumonia and cardiac failure 1.5 months after RTX infusion). Conclusion. This large EUSTAR cohort study points at positive effects of RTX in particular on skin fibrosis, and suggests randomized controlled trial in SSc patients

Published
2017

16. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study

Author

Sarzi-Puttini, P., Bianchino, L., Francesca Benaglio, Tirri, R., Salaffi, F., Pomponio, G., Cerinic, M. Matucci, Govoni, M., Gerli, R., Ferraccioli, G., Bombardieri, S., Idolazzi, L., and Caporali, R.

Subjects
Adult, Male, rheumatoid arthritis, tocilizumab, rheumatoid arthritis, clinical practice, Tumor Necrosis Factor-alpha, TRUST study, Middle Aged, Antibodies, Monoclonal, Humanized, Tocilizumab, rheumatoid arthritis, TRUST study, Receptors, Interleukin-6, NO, clinical practice, Arthritis, Rheumatoid, tocilizumab, Antirheumatic Agents, Humans, Female, Aged
Abstract

To describe the effectiveness and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, in a cohort of patients with rheumatoid arthritis (RA) recruited in clinical practice.TRUST was an observational study in RA patients who started treatment with TCZ in the 6 months prior to site activation and were still on treatment at start of study; patients were followed up to 12 months after the first TCZ infusion.322 RA patients were enrolled in 59 Italian centres (mean age: 55.8 years; mean disease duration: 120.5 months; baseline DAS28: 5.3). After 6 months of TCZ treatment, patients achieving low disease activity (DAS28 ≤3.2; 57.52%) or disease remission (DAS282.6; 38.05%) were 216 out of 226 patients with available DAS28 (p0.001). No statistically significant differences were found in mean DAS28 and HAQ score changes from baseline (start of TCZ treatment) to study end between patients previously inadequately responding to disease-modifyinganti-rheumatic drugs (DMARD-IR) or to DMARDs plus tumour necrosis factor inhibitors (DMARD +TNFi-IR): both patient populations responded to TCZ. A statistically significant decrease in mean VAS Fatigue score (48.4 vs. 34.7; p=0.0025) at month 6 was observed. In patients treated with TCZ as monotherapy (32.61%), DAS28, VAS fatigue and HAQ scores decreased from baseline to any post-baseline time point. Overall, 62 patients (19.3%) prematurely discontinued TCZ treatment, 24 (7.5%) for safety reasons. Drug-related adverse events occurred in 92 patients (28.6%) (mostly 3 hypercholesterolaemia and leucopenia) and drug-related serious adverse events in 11 patients (3.4%).This study confirms the good effectiveness and safety profile of TCZ in real life RA patient care.

Published
2017

17. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: Results of an Italian observational study

Author

Caporali, R., Idolazzi, L., Bombardieri, S., Ferraccioli, G., Gerli, R., Govoni, M., Matucci-Cerinic, M., Pomponio, G., Salaffi, F., Tirri, R., Benaglio, F., Bianchino, L., Sarzi-Puttini, P., Adami, S., Afeltra, A., Altomonte, L., Arrigoni, E., Bagnato, G., Bianchi, G., Bucci, R. N., Caminiti, M., Cantini, F., Caputo, D., Carlino, G., Clerico, P., Colombelli, P., Corsaro, S. M., D Alessandro, G., Riso, L., Silva, S., D Errico, T., Di Matteo, L., Ferri, C., Foti, R., Fusaro, E., Gabrielli, A., Giacomelli, R., Lunardi, C., Malavolta, N., Martin Martin, L. S., Massarotti, M. S., Mazzone, A., Meschini, C., Migliore, A., Minisola, G., Monti, G., Muratore, M., Paoletti, F., Pappone, N., Passiu, G., Mario Pirisi, Pistone, G., Pozzi, M. R., Prandini, P., Provenzano, G., Ricioppo, A., Romeo, N., Russo, R., Saviola, G., Semeraro, A., Tartarelli, G., Tomietto, P., Valentini, G., Zuccaro, C., Caporali, Roberto, Idolazzi, Luca, Bombardieri, Stefano, Ferraccioli, Gianfranco, Gerli, Roberto, Govoni, Marcello, Matucci-Cerinic, Marco, Pomponio, Giovanni, Salaffi, Fausto, Tirri, Rosella, Benaglio, Francesca, Bianchino, Laura, Sarzi-Puttini, Piercarlo, Caporali, R., Adami, S., Afeltra, A., Altomonte, L., Arrigoni, E., Bagnato, G., Bianchi, G., Bombardieri, S., Bucci, R. N., Caminiti, M., Cantini, F., Caputo, D., Carlino, G., Clerico, P., Colombelli, P., Corsaro, S. M., D'Alessandro, G., De Riso, L., De Silva, S., D'Errico, T., Di Matteo, L., Ferraccioli, G., Ferri, C., Foti, R., Fusaro, E., Gabrielli, A., Gerli, R., Giacomelli, R., Govoni, M., Lunardi, C., Malavolta, N., Martin Martin, L. S., Massarotti, M. S., Matucci-Cerinic, M., Mazzone, A., Meschini, C., Migliore, A., Minisola, G., Monti, G., Muratore, M., Paoletti, F., Pappone, N., Passiu, G., Pirisi, M., Pistone, G., Pozzi, M. R., Prandini, P., Provenzano, G., Ricioppo, A., Romeo, N., Russo, R., Salaffi, F., Sarzi-Puttini, P., Saviola, G., Semeraro, A., Tartarelli, G., Tomietto, P., Valentini, G., and Zuccaro, C.

Subjects
Rheumatology, Interleukin-6, Immunology, Immunology and Allergy, Tocilizumab, Monotherapy, Rheumatoid arthriti
Abstract

Objective To describe the effectiveness and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, in a cohort of patients with rheumatoid arthritis (RA) recruited in clinical practice. Methods TRUST was an observational study in RA patients who started treatment with TCZ in the 6 months prior to site activation and were still on treatment at start of study; patients were followed up to 12 months after the first TCZ infusion. Results 322 RA patients were enrolled in 59 Italian centres (mean age: 55.8 years; mean disease duration: 120.5 months; baseline DAS28: 5.3). After 6 months of TCZ treatment, patients achieving low disease activity (DAS28 ≤3.2; 57.52%) or disease remission (DAS28 < 2.6; 38.05%) were 216 out of 226 patients with available DAS28 (p < 0.001). No statistically significant differences were found in mean DAS28 and HAQ score changes from baseline (start of TCZ treatment) to study end between patients previously inadequately responding to disease-modifyinganti-rheumatic drugs (DMARD-IR) or to DMARDs plus tumour necrosis factor inhibitors (DMARD +TNFi-IR): both patient populations responded to TCZ. A statistically significant decrease in mean VAS Fatigue score (48.4 vs. 34.7; p=0.0025) at month 6 was observed. In patients treated with TCZ as monotherapy (32.61%), DAS28, VAS fatigue and HAQ scores decreased from baseline to any post-baseline time point. Overall, 62 patients (19.3%) prematurely discontinued TCZ treatment, 24 (7.5%) for safety reasons. Drug-related adverse events occurred in 92 patients (28.6%) (mostly 3 hypercholesterolaemia and leucopenia) and drug-related serious adverse events in 11 patients (3.4%). Conclusion This study confirms the good effectiveness and safety profile of TCZ in real life RA patient care.

Published
2017

19. Psychometric properties of an index of three patient reportedoutcome (PRO) measures, termed the CLinical ARthritis Activity (PRO-CLARA) inpatients with rheumatoid arthritis. The NEW INDICES study

Author

Salaffi F, Migliore A, Scarpellini M, Corsaro SM, Laganà B, Mozzani F, Varcasia G, Pusceddu M, Pomponio G, Romeo N, Maier A, Foti R, Gasparini S, Bombardieri S., SCARPA, RAFFAELE, Salaffi, F, Migliore, A, Scarpellini, M, Corsaro, Sm, Laganà, B, Mozzani, F, Varcasia, G, Pusceddu, M, Pomponio, G, Romeo, N, Maier, A, Foti, R, Scarpa, Raffaele, Gasparini, S, and Bombardieri, S.

Subjects
Psychometric properties, rheumatoid arthriti, CLinical ARthritis Activity
Published
2010

21. Recommendations for the management of biofilm: a consensus document

Author

Bianchi, T., primary, Wolcott, R.D., additional, Peghetti, A., additional, Leaper, D., additional, Cutting, K., additional, Polignano, R., additional, Rosa Rita, Z., additional, Moscatelli, A., additional, Greco, A., additional, Romanelli, M., additional, Pancani, S., additional, Bellingeri, A., additional, Ruggeri, V., additional, Postacchini, L., additional, Tedesco, S., additional, Manfredi, L., additional, Camerlingo, Maria, additional, Rowan, S., additional, Gabrielli, A., additional, and Pomponio, G., additional

Published
2016
Full Text
View/download PDF

24. DUO Registry Group. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry

Author

Guillevin, L, Hunsche, E, Denton, Cp, Krieg, T, Schwierin, B, Rosenberg, D, Matucci Cerinic, M, DUO Registry Group Collaborators Raffier, B, Hirschi, M, Trautinger, F, Schmidt, P, Stetter, M, Hundstorfer, M, Reinhart, V, Monshi, B, Pirkhammer, D, Richter, L, Hamberger, N, Metz, S, Feldmann, R, Semmelweis, K, Lackner, K, Tomi, N, Kolle, H, Hafner, F, Brodmann, M, Kuen Spiegel, M, Minmair, G, Heil, Pm, Broil, H, Holzer, G, Illmer, X, Rintelen, B, Sautner, J, Takacs, M, Thun, M, Zemanova, I, Soukup, T, Smrzova, A, Bohmova, J, Prochazkova, L, Nemec, P, Fojtik, Z, Suchy, D, Becvar, R, Olsen, Ab, Sondergaard, Kh, Luosu jarvi, R, Vidqvist, Kl, Madaule, S, Beneton, N, Maillard, H, Charlanne, H, Granelbrocard, F, Hachulla, E, Hatron, Py, Jourdain, N, Lambert, M, Launay, D, Morell, S, Woijtasik, G, Skowron, F, Zenone, T, Dadban, A, Lok, C, Ferrandiz, D, Magybertrand, N, Moiton, Mp, Taieb, A, Balquiere, S, Belin, E, Droitcourt, C, Julien, S, Prey, S, Boulon, C, Constans, J, Doutre, Ms, Kostrzwewa, E, Richez, C, Greco, M, Misery, L, Sassolas, B, Collet, E, Berthier, S, Leguy Seguin, V, Imbert, B, Carpentier, P, Blaise, S, Couraud, A, Doeffel Hantz, V, Spars, A, Bezanahary, H, Boussely, N, Dumonteil, S, Fauchais, Al, Goudran, G, Loustaud Ratti, V, Manea, P, Vidal, E, Coppere, B, Desmursclavel, H, Girard Madoux MH, Hot, A, Ninet, J, Granel, B, Cohen, Jd, Keynote, A, Khau van Kien, A, Le Quellec, A, Riviere, S, Rullier, P, Bessis, D, Farcas, C, Bravetti, V, Moline, T, Wahl, D, Zuily, S, Granel Brocard, F, Agard, C, Durant, C, Fuzibet, Jg, Queyrel, V, Berezne, A, Mouthon, L, Cabane, J, Tiev, K, Toledano, C, Lazareth, I, Michon Pasturel, U, Priollet, P, Reguiai, Z, Cazaletslacoste, C, Jego, P, Letremy, A, Perlat, A, Duval Modeste AB, Chatelus, E, Chiffot, H, Sibillia, J, Sordet, C, Adoue, D, Couret, B, Moulis, G, Pugnet, G, Sailler, L, Diot, E, Gaches, F, Farge, D, Keshtmand, H, Frances, C, von Elling, A, Bora, D, Ebel, J, Ahmadi Simab, K, Klein, E, Hahn, K, Schulze, K, Rasche, C, Riemekasten, G, Lee, Hh, Deuschle, K, Mattat, K, Becker, M, Worm, M, Mensing, C, Klings, D, Mensing, H, Messall, J, Zuper, R, Eilbacher, P, Saar, P, Kaufmann, P, Hallermann, C, Schmidt, K, Wahn, H, Schildt, K, Schuart, T, Kaczmarczyk, A, Kellner, C, von Oelhafen, J, Baron von Bildering, P, Kunze, S, Kleiner, Hj, Alsheimer, B, Schuetz, N, Miirker Hermann, E, Gottl, Kh, Weiss, E, Reischel, N, Kern, S, Goettl, Kh, Goetheuniversitiitsklinikum, Jw, Himsel, A, Henkemeier, U, Schwarting, A, Hazenbiller, A, Nichelmann, V, Rumbaur, C, Boesenberg, I, Schmeiser, T, Mueller Ladner, U, Unholzer, A, Starz, H, Welzel, J, Plaumann, K, Stoeckl, F, Sperling, S, Podda, M, Wagner, N, Rapprich, H, Niedermeier, A, Messer, G, Sardy, M, Bekou, V, Dill MUller, D, Wlodarz, M, Belloni, B, Huettig, B, Ziai, M, Hein, R, Kneitz, C, Federow, I, Schneider, K, Semmler, M, Hapke, S, Metzler, C, Stein, T, Enderlein, M, Kayser, M, Werthmann, M, Guenther, Cu, Neul, S, Hellmich, B, Loeffler, C, Pflugfelder, J, Karaenke, P, Mueglich, C, Tony, Hp, Marina, P, Popp, M, Mittag, M, Baumann, C, Scheib, Eg, Brand, H, Wilhelm, Hu, Bohm, J, Dyballa, J, Boehm, J, Taggeselle, J, Luthke, K, Wuerzburg, I, Niefanger, K, Mayer, L, Drabek, J, Harmuth, W, Dietl, S, Moritz, D, Gause, A, Gaubitz, M, Hallecker, A, Krupp, E, Rumpel, H, Moosig, F, Frey, P, Kahl, S, Linke, M, Merk, B, Bloching, Hh, Ochs, W, Kurthen, R, Eiden, E, Guertler, I, Aries, Pm, Kirchberg, S, Jahnke, K, Mettler, S, Toeller, S, Zwenger, S, Langer, He, Deininger, F, Hartmann, F, Neeck, G, Neek, G, Wernitzsch, H, Meier, L, Herr, U, Meier, U, Aaig, W, Bruckner, L, Sheikh, N, Wollenhaupt, J, Krog, B, Wollersdorfer, E, Hall, R, Diehm, C, Tiggers, C, Peters, J, Kirschke, J, Schroeder, Jo, Zeuner, R, Uhlig, S, Barth, S, Huegel, R, Glaeser, R, Schaefer, C, Monshausen, M, Mengden, T, Funkert, A, Blank, N, Lupaschko, S, Voss, B, Megahed, M, Sadeghlar, F, Seidel, M, Wasmuth, Jc, Kreuter, A, Vosswinkel, J, Pfoehler, C, Gerber, A, Haust, M, Hoff, Np, Mota, R, Akanay Diesel, S, Homey, B, Katzemich, A, Erfurt Berge, C, Sticherling, M, Beyer, C, Distler, J, Mitchell, A, Freundlieb, C, Rushentsova, U, Hermanns, G, Blaschke, S, Fiene, M, Wessel, C, Norgauer, J, Rabe, B, Schuster, J, Scholz, J, Kremer, K, Robakidze Torbahn, M, Moinzadeh, P, Dohse, A, Muhlack, A, Schultz, L, Schult, S, Frambach, Y, Kruse, S, Kettenbach, A, Fell, I, Schweda, K, Steinbrink, K, Podobinska, M, Fieri beck, G, Schanz, S, Pfeiffer, C, Hassel, R, Herrgott, I, Sunderkoetter, C, Guenzel, J, Athanassiou, P, Dimitroulas, T, Settas, L, Kritikos, I, Tsifetaki, N, Garyfallos, A, Vasilopoulos, D, Boura, P, Kamali, S, Aslanidis, S, Vlachoyannopoulos, P, Galanopoulo, V, Sakkas, L, Koutroubas, A, Elezoglou, T, Galanopoulos, N, Grier, A, Murray, M, O'Rourke, M, Del Papa, N, Maglione, W, Zeni, S, Foti, R, Benenati, A, De Vita, S, Ferraccioli, G, Grassi, W, de Angeli, R, Pomponio, G, Mussi, A, Colonna, L, Airo, P, Zingarelli, S, Scorza, R, Serverino, A, Puppo, F, Negrini, S, Roma, I, Salsano, F, Triolo, G, Mazzuca, S, Carignola, R, Gatti, S, Lunardi, G, Riccieri, V, Salvarani, C, Bajocchi, G, Varcasia, G, Marasini, B, Belloll, L, de Luca, R, Stisi, S, Bellissimo, S, Fusaro, E, Pellerito, R, Cozzi, F, Rizzo, M, Bartoluzzi, A, Trotta, F, Cantatore, F, Corrado, A, Ferri, Claudio, Colaci, M, Malavolta, N, Mule, R, Galeazzi, M, Lapadula, G, Mathieu, A, Vacca, A, Giacomelli, Roberto, Cipriani, Paola, Montecucco, Cm, Codullo, V, Bucci, R, Battaglia, E, Valentini, G, Cuomo, G, Terlizzi, N, Serafino, L, Reumatologia, Uo, Bombardieri, S, Della Rossa, A, Doveri, M, Perricone, R, de Mattia, M, Pallotta, S, Groenendael, Jh, Seys, P, Goekoop, Rj, Han, Kh, Wlarvens, M, Bonte Mineur, F, de Bois MH, de Beus WM, van Zeben, D, Vonk, M, Knaapen, Hk, Smit, A, Bootsma, H, Ton, E, Voskuyl, A, Dutmer, Ea, Stalk, Jn, Madland, Tm, Seip, M, Hoffmann Vold AM, Bitter, H, Stocklund Thomsen, R, Resende, C, Ponte, C, Martinho, S, Silva, F, Ferreira, P, Grilo, A, Riso, N, Santos, C, Camara, I, Costa, J, Alves, J, Oliveira, S, Almeida, I, Silva, I, Cordeiro, A, Coelho, P, Lukac, J, Dolnicar, As, Espinosa, G, Mejia, Jc, Ramos, M, Plasin Rodriguez MA, Mera, A, Blanco, Js, Diaz, Jj, Losada, L, Perez, E, Maneiro, Jr, Caamano, M, Fermindez, S, Insua, Sa, Barbado, J, Fonseca, Em, Nufio, Fj, Castellvi, I, Garcia de Ia Pena, P, Bellido, D, Paulino, M, Garcia, Pv, Salas, V, Minguez, Md, Sanchez, Ma, Urrego, C, Martin, I, Rueda, A, Calvo, J, Ripoll, Mm, Torres, Mc, Corteguera, M, Maceiras, F, Cruz, J, Mosquera, Ja, Gomez, R, Area, B, Carrio, I, Rubio, M, Castellvi Barranco, I, Santos, P, Simeon, Cp, Fonollosa, V, Egurbide, Mv, Garcia de Vicuna, R, Vicente, E, Villaverde, V, Fernandez, C, Garcia, E, Uson, J, Miguelez, R, Callejas, Jl, Ortego, N, Roman, J, Alegre Sancho JJ, Robles, A, Rios, Jj, Bonilla, Mg, Sanchez Andrade, A, Vazquez, Tr, Miranda, Ja, Saez, L, Zea, A, De la Puente, C, Martinez, Fg, Aguirre, Ma, Collado, P, Cruz, A, Crespo, M, Sanchez Roman, J, Castillo, Mj, Garcia, Am, Muniz, G, Hedin, Pj, Stahl, C, Bracin, T, Nordin, A, Albertsson, K, Rydvald, Y, Thorsson, C, Hermansson, E, Maurer, B, Verner, D, Schmidt Bosshard, R, Hall, F, Murphy, K, Lamb, J, Anderson, M, Moots, R, Buch, M, Bissell, L, Madhok, R, Hampson, R, D'Cruz, D, Choong, Lm, Gordon, P, Dobson, J, Salerno, R, Nisar, M, Williams, C, Wilcox, L, Denton, C, Ochiel, R, Ngcozana, T, Parker, L, Vincent, R, Mchugh, N, Cole, S, Brown, S, James, J, Herrick, A, Manning, J, Moore, T, Faizal, A, Skyes, H, Smythe, A, and Hamilton, A.

Published
2013

26. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

Author

Fraticelli, P, Gabrielli, B, Pomponio, G, Valentini, G, Bosello, S, Riboldi, P, Gerosa, M, Faggioli, P, Giacomelli, R, Del Papa, N, Gerli, R, Lunardi, C, Bombardieri, S, Malorni, W, Corvetta, A, Moroncini, G, Gabrielli, AAnna Maria Giammarioli, Giovanna Cuomo, Michele Iudici, Elena Bartoloni, Paola Cipriani, Lisa Gabbriellini, Silvia Svegliati, Donatella Amico, Matteo Marcosignori, Martina Bonifazi, Simona Giori, Fraticelli, P, Gabrielli, B, Pomponio, G, Valentini, Gabriele, Bosello, S, Riboldi, P, Gerosa, M, Faggioli, P, Giacomelli, R, Del Papa, N, Gerli, R, Lunardi, C, Bombardieri, S, Malorni, W, Corvetta, A, Moroncini, G, Gabrielli, A, on behalf of Imatinib in Scleroderma Italian Study, Group, Valentini, G, Gabrielli, AAnna Maria Giammarioli, Cuomo, Giovanna, Michele, Iudici, Elena, Bartoloni, Paola, Cipriani, Lisa, Gabbriellini, Silvia, Svegliati, Donatella, Amico, Matteo, Marcosignori, Martina, Bonifazi, and Simona, Giori

Subjects
Lung Diseases, Male, Pathology, Vital capacity, Settore MED/16 - REUMATOLOGIA, systemic sclerosis, Administration, Oral, Pilot Projects, Gastroenterology, Piperazines, Scleroderma, Immunosuppressive Agent, DLCO, Diffusing capacity, Immunology and Allergy, Tomography, Respiratory Function Test, Interstitial lung disease, Middle Aged, X-Ray Computed, Respiratory Function Tests, Treatment Outcome, Tolerability, Administration, Benzamides, Imatinib Mesylate, Female, Immunosuppressive Agents, Human, Research Article, Oral, Adult, medicine.medical_specialty, Immunology, Protein Kinase Inhibitor, FEV1/FVC ratio, Benzamide, Rheumatology, Internal medicine, medicine, Humans, Pilot Project, Cyclophosphamide, Lung Diseases, Interstitial, Protein Kinase Inhibitors, Pyrimidines, Scleroderma, Systemic, Tomography, X-Ray Computed, Piperazine, business.industry, Systemic, medicine.disease, Imatinib mesylate, Pyrimidine, Interstitial, business
Abstract

NTRODUCTION: Pulmonary involvement represents a major cause of death of systemic sclerosis (SSc) patients. Recent data suggest that tyrosine kinase inhibitors, such as imatinib, may be a therapeutic option for SSc patients. However, preliminary published clinical trials were inconclusive about imatinib efficacy and showed side effects. The purpose of this study was to verify efficacy and tolerability of low-dose imatinib on interstitial lung disease in a cohort of SSc patients unresponsive to cyclophosphamide therapy. METHODS: Thirty consecutive SSc patients with active pulmonary involvement, unresponsive to cyclophosphamide, were treated with imatinib 200 mg/day for 6 months followed by a 6-month follow-up. A "good response" was defined as an increase of forced vital capacity (FVC) by more of 15% and/or increase of diffusing capacity of carbon monoxide (DLCO) >15% and PaO2 > 90% of initial value and high-resolution computed tomography (HRCT)-scan pattern unchanged or improved. RESULTS: Twenty-six patients completed the study. Three patients died and one patient was lost to follow-up. Four patients (15.32%) had a good response, 7 worsened and 15 had a stabilized lung disease. Overall, 19 (73.07%) patients had an improved or stabilized lung disease. After a 6-month follow-up, 12 (54.5%) of the 22 patients showed an improved or stabilized lung disease. CONCLUSIONS: Lung function was stabilized in a large proportion of patients unresponsive to cyclophosphamide therapy and a beneficial outcome emerged from the analysis of HRCT lung scans. There was no significant improvement of skin involvement, and the low dose was well tolerated. These data provide useful suggestions to design future randomized clinical trials for SSc therapeutics. Introduction: Pulmonary involvement represents a major cause of death of systemic sclerosis (SSc) patients. Recent data suggest that tyrosine kinase inhibitors, such as imatinib, may be a therapeutic option for SSc patients. However, preliminary published clinical trials were inconclusive about imatinib efficacy and showed side effects. The purpose of this study was to verify efficacy and tolerability of low-dose imatinib on interstitial lung disease in a cohort of SSc patients unresponsive to cyclophosphamide therapy.Methods: Thirty consecutive SSc patients with active pulmonary involvement, unresponsive to cyclophosphamide, were treated with imatinib 200 mg/day for 6 months followed by a 6-month follow-up. A "good response" was defined as an increase of forced vital capacity (FVC) by more of 15% and/or increase of diffusing capacity of carbon monoxide (DLCO) > 15% and PaO2 > 90% of initial value and high-resolution computed tomography (HRCT)-scan pattern unchanged or improved.Results: Twenty-six patients completed the study. Three patients died and one patient was lost to follow-up. Four patients (15.32%) had a good response, 7 worsened and 15 had a stabilized lung disease. Overall, 19 (73.07%) patients had an improved or stabilized lung disease. After a 6-month follow-up, 12 (54.5%) of the 22 patients showed an improved or stabilized lung disease.Conclusions: Lung function was stabilized in a large proportion of patients unresponsive to cyclophosphamide therapy and a beneficial outcome emerged from the analysis of HRCT lung scans. There was no significant improvement of skin involvement, and the low dose was well tolerated. These data provide useful suggestions to design future randomized clinical trials for SSc therapeutics.

Published
2014

27. L’uso dei farmaci biologici durante la gravidanza e l’allattamento

Author

Favalli, E. G., Mancarella, L., Paoletti, F., Pomponio, G., Sandri, Gilda, Scioscia, C., Selvi, E., Tirri, E., D’Errico, T., Epis, O., and Garau, P.

Subjects
Arthritis, rheumatoid - Pregnancy - Tumor necrosis factor-alpha - Etanercept - Monoclonal antibodies - Rituximab - Certolizumab - Tocilizumab - Abatacept - Disease-modifying antirheumatic drugs, Arthritis, rheumatoid - Pregnancy - Tumor necrosis factor-alpha - Etanercept - Monoclonal antibodies - Rituximab - Certolizumab - Tocilizumab - Abatacept - Disease-modifying antirheumatic drugs
Published
2012

28. Efficacia e sicurezza delle vaccinazioni anti-influenza e anti-pneumococco nei pazienti con artrite reumatoide trattati con farmaci biologici

Author

Pomponio, G., Rovinelli, M., Scioscia, C., Selvi, E., Tirri, E., D’Errico, T., Epis, O., Favalli, E. G., Garau, P., Mancarella, L., Paoletti, F., and Sandri, Gilda

Subjects
Arthritis, Arthritis, rheumatoid - Tumor necrosis factor-alpha - Influenza vaccines - Pneumococcal vaccines, rheumatoid - Tumor necrosis factor-alpha - Influenza vaccines - Pneumococcal vaccines
Published
2012

30. Farmaci biologici ed epatiti da virus B e C

Author

D’Errico, T., Tirri, E., Favalli, E. G., Garau, P., Mancarella, L., Paoletti, F., Pomponio, G., Sandri, Gilda, Scioscia, C., Selvi, E., and Epis, O.

Subjects
Arthritis, Arthritis, rheumatoid - Hepatitis B - Hepatitis C - Tumor necrosis factor-alpha - Antiviral agents, rheumatoid - Hepatitis B - Hepatitis C - Tumor necrosis factor-alpha - Antiviral agents
Published
2012

31. Reazioni cutanee e terapia con anti-TNF-α

Author

Mancarella, L., Meliconi, R., Sandri, Gilda, Scioscia, C., Selvi, E., Tirri, E., D’Errico, T., Epis, O., Favalli, E. G., Garau, P., Paoletti, F., and Pomponio, G.

Subjects
rheumatoid - Skin diseases - Psoriasis - Tumor necrosis factor-alpha, Arthritis, Arthritis, rheumatoid - Skin diseases - Psoriasis - Tumor necrosis factor-alpha
Published
2012

32. Farmaci biologici e tematiche relative alla cardiopatia ischemica e all’insufficienza cardiaca

Author

Garau, P., D’Errico, T., Epis, O., Favalli, E. G., Mancarella, L., Paoletti, F., Pomponio, G., Sandri, Gilda, Scioscia, C., Selvi, E., and Tirri, E.

Subjects
Arthritis, Arthritis, rheumatoid - Tumor necrosis factor-alpha - Cardiovascular diseases - Myocardial infarction - Heart failure, rheumatoid - Tumor necrosis factor-alpha - Cardiovascular diseases - Myocardial infarction - Heart failure
Published
2012

34. Farmaci biologici e infezione tubercolare

Author

Scioscia, C., Anelli, M. G., Epis, O., Favalli, E. G., Garau, P., Mancarella, L., Paoletti, F., Pomponio, G., Sandri, Gilda, Selvi, E., Tirri, E., and D’Errico, T.

Subjects
rheumatoid - Tumor necrosis factor-alpha - Antibodies, Arthritis, Arthritis, rheumatoid - Tumor necrosis factor-alpha - Antibodies, monoclonal - Tuberculosis, monoclonal - Tuberculosis
Published
2012

35. Farmaci biologici e rischio oncologico

Author

Sandri, Gilda, Paoletti, F., Pomponio, G., Scioscia, C., Selvi, E., Tirri, E., D’Errico, T., Epis, O., Favalli, E. G., Garau, P., and Mancarella, L.

Subjects
Arthritis, rheumatoid - Neoplasms - Lymphoma - Tumor necrosis factor-alpha, rheumatoid - Neoplasms - Lymphoma - Tumor necrosis factor-alpha, Arthritis
Published
2012

36. SAT0259 Patient Reported Outcomes and Quality of Life in a Cohort of Patients Affected by Entheropathic Spondyloarthritis: Preliminary Results from a Monocentric Prospective Observational Study

Author

Luchetti, M.M., primary, Balloni, A., additional, Benfaremo, D., additional, Bolognini, L., additional, Farinelli, A., additional, Cedraro, S., additional, Rossini, M., additional, Capeci, W., additional, Manfredi, L., additional, Postacchini, L., additional, Tedesco, S., additional, Fava, G., additional, Lorenzini, I., additional, Pomponio, G., additional, and Gabrielli, A., additional

Published
2015
Full Text
View/download PDF

37. THU0219 Effect of Adalimumab Therapy on Both Gastrointestinal and Articular Inflammation at 6 Months in Patients Affected by Enteropathic Spondyloarthritis: Preliminary Results from a Monocentric Prospective Observational Study

Author

Luchetti, M.M., primary, Benfaremo, D., additional, Balloni, A., additional, Bolognini, L., additional, Farinelli, A., additional, Cedraro, S., additional, Rossini, M., additional, Capeci, W., additional, Manfredi, L., additional, Postacchini, L., additional, Tedesco, S., additional, Fava, G., additional, Lorenzini, I., additional, Pomponio, G., additional, and Gabrielli, A., additional

Published
2015
Full Text
View/download PDF

45. SAT0213 Low-Dose Imatinib in the Treatment of Scleroderma Pulmonary Involvement: Results of a Phase II Pilot Study.

Author

Fraticelli, P., primary, Pomponio, G., additional, Gabrielli, B., additional, Riboldi, P., additional, Ferraccioli, G., additional, Giacomelli, R., additional, Del Papa, N., additional, Bombardieri, S., additional, Malorni, W., additional, Gerli, R., additional, Lunardi, C., additional, Faggioli, P., additional, Corvetta, A., additional, Valentini, G., additional, and Gabrielli, A., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results